136 related articles for article (PubMed ID: 37121122)
1. Risk signature identification and NPRL2 affects sunitinib sensitivity in clear cell renal cell carcinoma.
Du X; Zhao Z; Zhao X; Wang H; Jiang L; Tang W
Biochem Biophys Res Commun; 2023 Jun; 663():122-131. PubMed ID: 37121122
[TBL] [Abstract][Full Text] [Related]
2. Decreased expression of NPRL2 in renal cancer cells is associated with unfavourable pathological, proliferation and apoptotic features.
Tang Y; Jiang L; Tang W
Pathol Oncol Res; 2014 Oct; 20(4):829-37. PubMed ID: 24789683
[TBL] [Abstract][Full Text] [Related]
3. Key sunitinib-related biomarkers for renal cell carcinoma.
Peng Y; Dong S; Song Y; Hou D; Wang L; Li B; Wang H
Cancer Med; 2021 Oct; 10(19):6917-6930. PubMed ID: 34402193
[TBL] [Abstract][Full Text] [Related]
4. Low DAPK1 expression correlates with poor prognosis and sunitinib resistance in clear cell renal cell carcinoma.
Song Z; Li Z; Han W; Zhu C; Lou N; Li X; Luo G; Peng S; Li G; Zhao Y; Guo Y
Aging (Albany NY); 2020 Nov; 13(2):1842-1858. PubMed ID: 33201837
[TBL] [Abstract][Full Text] [Related]
5. YTHDC1 is downregulated by the YY1/HDAC2 complex and controls the sensitivity of ccRCC to sunitinib by targeting the ANXA1-MAPK pathway.
Li W; Ye K; Li X; Liu X; Peng M; Chen F; Xiong W; Wang Y; Zhu L
J Exp Clin Cancer Res; 2022 Aug; 41(1):250. PubMed ID: 35974388
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive analysis of cellular senescence-related genes in the prognosis, tumor microenvironment, and immunotherapy/chemotherapy of clear cell renal cell carcinoma.
Lu C; Wang Y; Nie L; Chen L; Li M; Qing H; Li S; Wu S; Wang Z
Front Immunol; 2022; 13():934243. PubMed ID: 36189255
[TBL] [Abstract][Full Text] [Related]
7. Establishment of Sunitinib-Resistant Xenograft Model of Renal Cell Carcinoma and the Identification of Drug-Resistant Hub Genes and Pathways.
Xie Y; Shangguan W; Chen Z; Zheng Z; Chen Y; Zhong Q; Zhang Y; Yang J; Zhu D; Xie W
Drug Des Devel Ther; 2021; 15():5061-5074. PubMed ID: 34938069
[TBL] [Abstract][Full Text] [Related]
8. Identification of molecular subtypes based on chromatin regulator and tumor microenvironment infiltration characterization in papillary renal cell carcinoma.
Tang Q; Pan D; Xu C; Chen L
J Cancer Res Clin Oncol; 2023 Jan; 149(1):231-245. PubMed ID: 36404389
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of VHL, HIF1A, HIF2A, VEGFA and p53 expression in patients with clear‑cell renal cell carcinoma treated with sunitinib as first‑line treatment.
Wierzbicki PM; Klacz J; Kotulak-Chrzaszcz A; Wronska A; Stanislawowski M; Rybarczyk A; Ludziejewska A; Kmiec Z; Matuszewski M
Int J Oncol; 2019 Aug; 55(2):371-390. PubMed ID: 31268155
[TBL] [Abstract][Full Text] [Related]
10. Role of IL13RA2 in Sunitinib Resistance in Clear Cell Renal Cell Carcinoma.
Shibasaki N; Yamasaki T; Kanno T; Arakaki R; Sakamoto H; Utsunomiya N; Inoue T; Tsuruyama T; Nakamura E; Ogawa O; Kamba T
PLoS One; 2015; 10(6):e0130980. PubMed ID: 26114873
[TBL] [Abstract][Full Text] [Related]
11. Dyskerin and telomerase RNA component are sex-differentially associated with outcomes and Sunitinib response in patients with clear cell renal cell carcinoma.
Yuan H; Qin X; Yang Q; Liu L; Fang Z; Fan Y; Xu D
Biol Sex Differ; 2023 Jul; 14(1):46. PubMed ID: 37434223
[TBL] [Abstract][Full Text] [Related]
12. PRMT1 is a novel molecular therapeutic target for clear cell renal cell carcinoma.
Wang J; Wang C; Xu P; Li X; Lu Y; Jin D; Yin X; Jiang H; Huang J; Xiong H; Ye F; Jin J; Chen Y; Xie Y; Chen Z; Ding H; Zhang H; Liu R; Jiang H; Chen K; Yao Z; Luo C; Huang Y; Zhang Y; Zhang J
Theranostics; 2021; 11(11):5387-5403. PubMed ID: 33859753
[No Abstract] [Full Text] [Related]
13. Computational construction of TME-related lncRNAs signature for predicting prognosis and immunotherapy response in clear cell renal cell carcinoma.
Zhou L; Fang H; Guo F; Yin M; Long H; Weng G
J Clin Lab Anal; 2022 Aug; 36(8):e24582. PubMed ID: 35808868
[TBL] [Abstract][Full Text] [Related]
14. RCAN1.4 acts as a suppressor of cancer progression and sunitinib resistance in clear cell renal cell carcinoma.
Song Z; Cao Q; Ruan H; Yang H; Wang K; Bao L; Cheng G; Xu T; Xiao H; Wang C; Liu D; Chen K; Zhang X
Exp Cell Res; 2018 Nov; 372(2):118-128. PubMed ID: 30267660
[TBL] [Abstract][Full Text] [Related]
15. VHL mutation-mediated SALL4 overexpression promotes tumorigenesis and vascularization of clear cell renal cell carcinoma via Akt/GSK-3β signaling.
Sun J; Tang Q; Gao Y; Zhang W; Zhao Z; Yang F; Hu X; Zhang D; Wang Y; Zhang H; Song B; Zhang B; Wang H
J Exp Clin Cancer Res; 2020 Jun; 39(1):104. PubMed ID: 32513235
[TBL] [Abstract][Full Text] [Related]
16. An immune-related lncRNA risk coefficient model to predict the outcomes in clear cell renal cell carcinoma.
Tang C; Qu G; Xu Y; Yang G; Wang J; Xiang M
Aging (Albany NY); 2021 Dec; 13(24):26046-26062. PubMed ID: 34954690
[TBL] [Abstract][Full Text] [Related]
17. Upregulation of serine metabolism enzyme PSAT1 predicts poor prognosis and promotes proliferation, metastasis and drug resistance of clear cell renal cell carcinoma.
Ye J; Huang X; Tian S; Wang J; Wang H; Feng H; Zhao X; Cao S; Xuan Y; Li X; Ma X; Huang Y; Zhang X
Exp Cell Res; 2024 Apr; 437(1):113977. PubMed ID: 38373588
[TBL] [Abstract][Full Text] [Related]
18. Epithelial-mesenchymal transition as a mechanism of resistance to tyrosine kinase inhibitors in clear cell renal cell carcinoma.
Hwang HS; Go H; Park JM; Yoon SY; Lee JL; Jeong SU; Cho YM
Lab Invest; 2019 May; 99(5):659-670. PubMed ID: 30683903
[TBL] [Abstract][Full Text] [Related]
19. Elevated SNRPA1, as a Promising Predictor Reflecting Severe Clinical Outcome
Jiang A; Meng J; Gong W; Zhang Z; Gan X; Wang J; Wu Z; Liu B; Qu L; Wang L
Front Immunol; 2022; 13():842069. PubMed ID: 35281041
[TBL] [Abstract][Full Text] [Related]
20. Exosomal microRNA-15a from ACHN cells aggravates clear cell renal cell carcinoma via the BTG2/PI3K/AKT axis.
Li DY; Lin FF; Li GP; Zeng FC
Kaohsiung J Med Sci; 2021 Nov; 37(11):973-982. PubMed ID: 34337864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
